← back to search

Li Zhang

Shandong Academy of Pharmaceutical Sciences · CN
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, and Cancer-related molecular mechanisms research.
h-index
114
citations
75,024
works
4,056
NIH funding
primary concept
email

Recent publications

Correlation of unfavourable and favourable histology at radical prostatectomy with Decipher scores and freedom from biochemical recurrence.
2026cited by 1position: contributordoi
Correlation of lymphocytic infiltration and degree of pleomorphism with tumor mutation burden in high-grade urothelial carcinoma.
2026cited by 0position: contributordoi
Characterization of small intestinal neuroendocrine tumorlets.
2026cited by 0position: contributordoi
Phase II trial with nivolumab and sorafenib in HCC identified enrichment of immunosuppressive monocytes in patients with Child-Pugh B liver dysfunction.
2026cited by 0position: contributordoi
Feasibility and Implementation of INTERVAL-GAP4: A Global Randomised Controlled Trial of Intense Hybrid-supervised/Self-managed Versus Self-directed Exercise for Metastatic Prostate Cancer.
2026cited by 0position: contributordoi
Prevalence of High-Risk Human Papillomavirus and Associated Risk Factors Among Individuals With Head and Neck Cancer in a National Referral Center in Tanzania.
2026cited by 0position: contributordoi
Effective Strategies for Teaching Machine Learning
Proceedings of the AAAI Conference on Artificial Intelligence 2026cited by 0position: lastdoi
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
JAMA 2025cited by 64position: middledoi
Targeting PIKfyve-driven lipid metabolism in pancreatic cancer
Nature 2025cited by 31position: middledoi
The Effect of Low-Dose Aspirin on Disease Activity in Pregnant Individuals With Inflammatory Bowel Disease.
2025cited by 9position: contributordoi
PROX1 is an early driver of lineage plasticity in prostate cancer
Journal of Clinical Investigation 2025cited by 8position: middledoi
Administration practices of and adherence to nusinersen in children with spinal muscular atrophy: a multicenter disease registry study in China
BMC Pediatrics 2025cited by 5position: middledoi
Factors associated with grade progression in pancreatic neuroendocrine tumors.
2025cited by 4position: contributordoi
Body Composition Differentiates Prediabetes Phenotype Clusters in the Diabetes Prevention Program Study.
2025cited by 3position: contributordoi
Evaluating adverse events of pegvaliase-pqpz in phenylketonuria treatment: A comprehensive safety assessment
SAGE Open Medicine 2025cited by 3position: middledoi
Identification and regulation of circulating tumor-TCR-matched cytotoxic CD4+ lymphocytes by KLRG1 in bladder cancer.
2025cited by 2position: contributordoi
A Primary Care Group Resilience Intervention Promotes Child and Caregiver Behavioral Health.
2025cited by 2position: contributordoi
Role of Menstrual Bleeding Assessments in Sickle Cell Clinics.
2025cited by 1position: contributordoi
Burdens of Gastroenteropancreatic Neuroendocrine Neoplasm by Diverse Race and Ethnicities- A Rigorous Structural Equation Modeling.
2025cited by 1position: contributordoi
Differences and clinical significance of liver - kidney function parameters, inflammatory markers and peripheral blood T lymphocyte subsets in patients with HBV - related acute - on - chronic liver failure
BMC Gastroenterology 2025cited by 1position: middledoi
PepTCR-Net: prediction of multi-class antigen peptides by T-cell receptor sequences with deep learning.
2025cited by 0position: contributordoi
Investigating research study participant compensation practices at a California academic and research institution.
2025cited by 0position: contributordoi
Treatment Outcomes of Esophageal Cancer in Malawi: An Analysis of Overall Survival and Patient-Reported Outcomes.
2025cited by 0position: contributordoi
Figure S2 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
2025cited by 0position: contributordoi
Supplementary Table 2. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2025cited by 0position: contributordoi
Supplementary Table 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2025cited by 0position: contributordoi
Figure S7 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
2025cited by 0position: contributordoi
Supplementary Data 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2025cited by 0position: contributordoi
Data from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
2025cited by 0position: contributordoi
Supplementary Table 3. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2025cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 308 papers (2019–2026)Emily Chan · Chulalongkorn University203 papers (2022–2025)Robert R. Flavell · University of San Francisco182 papers (2023–2025)Youngho Seo · Pusan National University180 papers (2023–2025)Kondapa Naidu Bobba · University of California, San Francisco180 papers (2023–2025)Yang Su · University of California, San Francisco180 papers (2023–2025) · 180 papers (2023–2025) · 180 papers (2023–2025)David M. Wilson · AstraZeneca (Singapore)180 papers (2023–2025)Sinan Wang · ShanghaiTech University180 papers (2023–2025)Suchi Dhrona · University of California, San Francisco180 papers (2023–2025)Anil P. Bidkar · University of California, San Francisco180 papers (2023–2025)Henry F. VanBrocklin · University of San Francisco180 papers (2023–2025)Niranjan Meher · National Institute of Pharmaceutical Education and Research180 papers (2023–2025)Scott Bidlingmaier · University of California, San Francisco180 papers (2023–2025)Anju Wadhwa · University of California, San Francisco180 papers (2023–2025)Rahul Aggarwal · Dr. B. R. Ambedkar National Institute of Technology Jalandhar121 papers (2022–2025) · 109 papers (2022–2025)Huimin Geng · University of California, San Francisco94 papers (2024–2024)Arun P. Wiita · The Neurological Institute94 papers (2024–2024)